Filana Therapeutics adds biopharma executive Jill Quigley to board
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing
4 stories
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing
Emil Kuriakose and Michael Vasconcelles join as independent directors effective October 30, 2026, expanding the board to eleven members.
SEC filing
Merck reported $18.1 billion in third-quarter sales and detailed FDA approvals, a priority BLA filing for sac-TMT, and new guidance including one-time charges tied to the Cidara and Terns deals.
SEC filing (2)